Humacyte Inc (HUMA)
4.615
+0.08
(+1.65%)
USD |
NASDAQ |
May 07, 16:00
4.615
0.00 (0.00%)
After-Hours: 20:00
Humacyte Total Liabilities (Quarterly): 114.68M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 114.68M |
| September 30, 2023 | 112.39M |
| June 30, 2023 | 106.99M |
| March 31, 2023 | 101.09M |
| December 31, 2022 | 87.37M |
| September 30, 2022 | 107.55M |
| Date | Value |
|---|---|
| June 30, 2022 | 104.10M |
| March 31, 2022 | 160.58M |
| December 31, 2021 | 164.36M |
| September 30, 2021 | 227.50M |
| December 31, 2020 | 457.00M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
87.37M
Minimum
Dec 2022
457.00M
Maximum
Dec 2020
158.51M
Average
112.39M
Median
Sep 2023
Total Liabilities (Quarterly) Benchmarks
| Adial Pharmaceuticals Inc | 0.6531M |
| Gritstone Bio Inc | 125.92M |
| Precision BioSciences Inc | 140.92M |
| Puma Biotechnology Inc | 163.17M |
| Revance Therapeutics Inc | 630.06M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 128.22M |
| Shareholders Equity (Quarterly) | 13.55M |